AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

Business

A healthcare professional draws up a dose of the Oxford/AstraZeneca Covid-19 vaccine at the vaccination centre set up inside Brighton Centre in Brighton, southern England, on January 26, 2021.
Ben Stensall | AFP | Getty Images

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% against severe disease and hospitalization.

The results were published Monday

It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.

Germany, France, Italy and Spain are among those that have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is safe and effective.

This is a developing story and will be updated shortly.

Articles You May Like

Watch Jerome Powell testify to Congress on the economy and how the Fed plans to fight inflation
With or without a federal gas tax holiday, here are 4 ways to save money at the pump
Winnebago Finds Buyers After Earnings Beat
WWE boss Vince McMahon steps away from CEO role, will address misconduct probe on ‘Smackdown’
Testimony: Pennsylvania Should Respond to Inflation with Structural Tax Reforms